IAC (028) 35 11 33 33 Emergency (028) 35 11 35 00 Financial Information FV Subsidy Programme IAC (028) 35 11 33 33 Emergency (028) 35 11 35 00 Financial Information FV Subsidy Programme Reducing financial burden through subsidies of up to 20%, interest-free installment options, and an oncology medicine assistance programme. Subsidy of up to 20% for Uninsured Patients FV Hospital offers a healthcare subsidy scheme for patients without health insurance, providing up to 20% discount on eligible services. Who qualifies? This subsidy is available ONLY to patients without private health insurance, regardless of whether they have social health insurance. This subsidy is NOT applicable to patients whose treatment costs are covered by private health insurance, regardless of whether the insurer has a direct billing agreement with FV Hospital. Installment Plan Since January 2025, you can pay your hospital fees in monthly installments so you can focus on recovery, not finances. How it works The plan is available for payments made with credit cards issued by participating banks that have a cooperation agreement with FV Hospital in Vietnam. For the list of partner banks, call our hotline: : (028) 35 11 33 33 For any service paid by credit card with a minimum transaction of VND10 million, cardholders can convert the payment into an installment plan lasting 3 to 12 months. Exclusive Offer For a 3-month instalment term, the conversion fee is fully waived and covered by FV Hospital. For installment terms of 6 months or longer, the conversion fee is paid by you. Oncology Medicine Assistance Programme FV Hospital has partnered with reputable global pharmaceutical manufacturers to offer patients a “Partial Medicine Assistance Programme,” also known as a “Patient Support Programme.” This initiative covers branded, high-cost oncology medicines not included in the social health insurance reimbursement list. The programme has been approved by the Ministry of Health for implementation at select hospitals nationwide. Its purpose is to reduce patients’ financial burden, enabling access to more effective treatments, adherence to prescribed regimens, and improved treatment outcomes and quality of life. *Programme validity periods vary by medicine. Please consult the Pharmacy or Oncology Department for the most up-to-date information. Eligibility: The programme applies to all patients who are examined at FV and have a prescription from a doctor for one of the medicines described above. Patients must be provided with the terms and conditions and application period of the programme before making a decision. Patients must sign an agreement when participating in the programme. The programme applies until a patient stops their treatment according to their doctor’s direction, or when they decide to stop participating in the programme, or when the programme expires. Tagrisso (Osimertinib) Valid until: December 31, 2029 Indication Tagrisso (osimertinib) is approved for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or the EGFR T790M resistance mutation. It is also approved as adjuvant therapy after complete tumour resection in adults with stage IB–IIIA NSCLC with EGFR exon 19 deletions or exon 21 L858R point mutations. Support programme Months 1–6 (Support Level 1): After self-funding 1 treatment cycle, the patient receives 1 cycle free of charge. Months 7–24 (Support Level 2): After self-funding 1 cycle, the patient receives 2 cycles free of charge. From month 25 onward (Support Level 3): After self-funding 1 cycle, the patient receives 3 cycles free of charge. Imfinzi (Durvalumab) Valid until: December 31, 2028 Indication Imfinzi (durvalumab) is approved for adults with unresectable stage III NSCLC whose disease has not progressed after concurrent platinum-based chemoradiotherapy. In combination with etoposide and carboplatin or cisplatin, Imfinzi is also approved as a first-line treatment for adults with extensive-stage small cell lung cancer (ES-SCLC). Biliary tract cancer (BTC): In combination with gemcitabine and cisplatin, Imfinzi is approved for adults with locally advanced or metastatic biliary tract cancer. Hepatocellular carcinoma (HCC): In combination with tremelimumab, Imfinzi is approved for adults with unresectable hepatocellular carcinoma (uHCC). Support programme Fixed-dose patients (1,500 mg): For every 1 box of Imfinzi 500 mg purchased, the patient receives 2 boxes of Imfinzi 500 mg free of charge. Weight-based dosing for patients: For every 1 treatment cycle of Imfinzi, the patient receives 1 cycle free of charge Lynparza (Olaparib) Valid until: December 31, 2029 Indication Lynparza (olaparib) is indicated for patients with ovarian cancer, breast cancer, fallopian tube cancer, pancreatic cancer, and prostate cancer, across the following specific settings: Newly diagnosed advanced ovarian cancer with BRCA mutation (monotherapy) Newly diagnosed advanced ovarian cancer with homologous recombination deficiency (HRD-positive), in combination with bevacizumab Relapsed platinum-sensitive ovarian cancer, with or without BRCA mutation Early-stage, high-risk breast cancer with germline BRCA mutation and HER2-negative disease Locally advanced or metastatic breast cancer with germline BRCA mutation and HER2-negative disease Metastatic castration-resistant prostate cancer with HRR gene mutations, in combination with abiraterone and prednisone or prednisolone, in patients not indicated for chemotherapy Monotherapy in patients with pathogenic or suspected pathogenic HRR gene mutations who have progressed after treatment with a new hormonal agent Metastatic pancreatic adenocarcinoma with germline BRCA mutation Support programme For every 1 self-funded treatment cycle of Lynparza, the patient receives 3 treatment cycles free of charge. KEYTRUDA (Pembrolizumab) Valid until: December 31, 2026 Indication KEYTRUDA (pembrolizumab) is indicated for the treatment of patients with the following cancer types: (1) melanoma; (2) non-small cell lung cancer (NSCLC); (3) classical Hodgkin lymphoma; (4) urothelial carcinoma; (5) head and neck cancer; (6) gastric cancer; (7) microsatellite instability-high (MSI-H) cancers; (8) cervical cancer; (9) hepatocellular carcinoma (HCC); (10) MSI-H or mismatch repair-deficient (dMMR) colorectal cancer; (11) primary mediastinal large B-cell lymphoma; (12) oesophageal cancer; (13) triple-negative breast cancer (TNBC); and (14) renal cell carcinoma. Support programme Level 1: For every 1 vial of KEYTRUDA self-funded (200 mg every 3 weeks), the patient receives 1 vial free per treatment cycle. Adult patients self-funding 2 vials (400 mg every 6 weeks) receive 2 vials free per cycle. Level 2 — per every 4 treatment cycles: In the first 3 cycles, the patient self-funds 1 vial and receives 1 vial free per cycle. In the 4th cycle, the patient receives treatment at no cost (200 mg every 3 weeks). Alternatively, in the first 3 cycles, the patient self-funds 2 vials and receives 2 vials free. In the 4th cycle, treatment is entirely free of charge (400 mg every 6 weeks). This tier applies only to adult patients. Level 3 — per every 4 treatment cycles: In the first 2 cycles, the patient self-funds 1 vial and receives 1 vial free per cycle. In the subsequent 2 cycles, treatment is entirely free of charge (200 mg every 3 weeks). Alternatively, in the first 2 cycles, the patient self-funds 2 vials and receives 2 vials free. In the subsequent 2 cycles, treatment is entirely free of charge (400 mg every 6 weeks). This tier applies only to adult patients. After 24 consecutive treatment cycles at 200 mg every 3 weeks, or 12 consecutive cycles at 400 mg every 6 weeks, the patient is eligible to receive a further 11 cycles free at the 200 mg/3-week dose, or 6 cycles free at the 400 mg/6-week dose — provided the patient remains eligible for ongoing KEYTRUDA treatment. TECENTRIQ (Atezolizumab) Valid until: December 31, 2026 Indication TECENTRIQ (atezolizumab) is indicated for the treatment of early-stage NSCLC, metastatic NSCLC, small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), and metastatic urothelial carcinoma. Support programme The patient self-funds 1 vial of TECENTRIQ (1,200 mg) at cycles 1, 3, and 4 and receives 1 vial free of charge at cycles 2 and 5. Calquence (Acalabrutinib) Valid until: December 31, 2033 Indication Calquence (acalabrutinib) is indicated for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy, chronic lymphocytic leukaemia (CLL), or small lymphocytic lymphoma (SLL). Support programme After 1 self-funded cycle of Calquence, the patient receives 2 cycles free of charge. On this page Subsidy of up to 20% Installment Plan Oncology Medicine Assistance programme Need Assistance? For enquiries about financial support options, please call Hotline (028) 35 11 33 33
